Real-World Evidence in Drug Development and Evaluation | Agenda Bookshop Skip to content
Online orders placed from 19/12 onward will not arrive in time for Christmas.
Online orders placed from 19/12 onward will not arrive in time for Christmas.
Age Group_Uncategorized
Age Group_Uncategorized
automatic-update
B01=Binbing Yu
B01=Harry Yang
Category1=Non-Fiction
Category=MBGR
Category=MBGR1
Category=PBT
Category=PS
Category=TDCW
COP=United Kingdom
Delivery_Pre-order
Language_English
PA=Temporarily unavailable
Price_€100 and above
PS=Active
softlaunch

Real-World Evidence in Drug Development and Evaluation

English

Real-world evidence (RWE) has been at the forefront of pharmaceutical innovations. It plays an important role in transforming drug development from a process aimed at meeting regulatory expectations to an operating model that leverages data from disparate sources to aid business, regulatory, and healthcare decision making. Despite its many benefits, there is no single book systematically covering the latest development in the field.

Written specifically for pharmaceutical practitioners, Real-World Evidence in Drug Development and Evaluation, presents a wide range of RWE applications throughout the lifecycle of drug product development. With contributions from experienced researchers in the pharmaceutical industry, the book discusses at length RWE opportunities, challenges, and solutions.

Features

  • Provides the first book and a single source of information on RWE in drug development
  • Covers a broad array of topics on outcomes- and value-based RWE assessments
  • Demonstrates proper Bayesian application and causal inference for real-world data (RWD)
  • Presents real-world use cases to illustrate the use of advanced analytics and statistical methods to generate insights
  • Offers a balanced discussion of practical RWE issues at hand and technical solutions suitable for practitioners with limited data science expertise
See more
Current price €127.29
Original price €133.99
Save 5%
Age Group_Uncategorizedautomatic-updateB01=Binbing YuB01=Harry YangCategory1=Non-FictionCategory=MBGRCategory=MBGR1Category=PBTCategory=PSCategory=TDCWCOP=United KingdomDelivery_Pre-orderLanguage_EnglishPA=Temporarily unavailablePrice_€100 and abovePS=Activesoftlaunch

Will deliver when available.

Product Details
  • Weight: 720g
  • Dimensions: 156 x 234mm
  • Publication Date: 03 Mar 2021
  • Publisher: Taylor & Francis Ltd
  • Publication City/Country: United Kingdom
  • Language: English
  • ISBN13: 9780367026219

About

Harry Yang Ph.D. is Vice President and Head of Biometrics at Fate Therapeutics. He has 25 years of experience across all aspects of drug research and development from early target discovery through pre-clinical clinical and CMC programs to regulatory approval and post-approval lifecycle management. He has published 7 statistical books 15 book chapters and over 90 peer-reviewed papers on diverse scientific and statistical subjects. He is a frequent invited speaker at national and international conferences. He also developed statistical courses and conducted training at the FDA and USP.Binbing Yu Ph.D. is Associate Director in the Oncology Statistical Innovation group at AstraZeneca. He serves as the statistical expert across the whole spectrum of drug R&D including drug discovery clinical trials operation and manufacturing clinical pharmacology oncology medical affairs and post-marketing surveillance. He obtained his PhD in Statistics from the George Washington University. His primary research interests are clinical trial design and analysis cancer epidemiology causal inference in observation studies PKPD modeling and Bayesian analysis.

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept